Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development

Chengdu, China, 14 July 2021 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today appointment of Dr. Hong Liu as VP of Clinical Development. A physician-scientist, he will be based in Chengdu and San Francisco.

Read full release here.